Relief /
NRx Pharmaceuticals
Relief to receive NRx Pharmaceuticals aviptadil program assets
- Terms
- Undisclosed
- Stage
- Agreement signed
What happened
NRx Pharmaceuticals agreed to transfer to Relief the assets it previously used in its aviptadil development program, including regulatory filings, patent applications, clinical data and product formulation.
Relief will have exclusive control going forward and is to use commercially reasonable efforts to develop and commercialize an aviptadil product. Terms weren't disclosed.
The source
Everything on this page comes from the source below.
Relief to receive NRx Pharmaceuticals aviptadil program assets
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly